Brand Name

Ongentys

Generic Name
Opicapone
View Brand Information
FDA approval date: April 05, 2024
Classification: Catechol-O-Methyltransferase Inhibitor
Form: Capsule

What is Ongentys (Opicapone)?

ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. ONGENTYS is a catechol-O-methyltransferase inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.
Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.
Journal: Journal of Parkinson's disease
Published: April 17, 2026
Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.
Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.
Journal: Brain sciences
Published: March 21, 2026
Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.
Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.
Journal: Annals of medicine
Published: March 05, 2026
View All Latest Advances